Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 4,669 shares at $14.23 ($64K) on 2022-08-24, disclosed to the SEC on 2022-08-26.
Scheduled sale ($64k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.52 | 2,817 | $38K | 59.2% |
| 2 | $14.23 | 301 | $4K | 6.7% |
| 3 | $14.18 | 1,551 | $22K | 34.2% |
| Total | $13.79 avg | 4,669 | $64K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |